StrataGraft burn-healing tissue gets fast-track boost from the FDA

A skin tissue product to treat serious burns — developed and manufactured in Madison — will get special attention from the FDA.

StrataGraft is one of the first products to be designated as a “regenerative medicine advanced therapy” by the U.S. Food and Drug Administration. That means it could qualify for priority review and faster approval, said Steven Romano, executive vice president and chief scientific officer of Mallinckrodt, the global pharmaceutical company that owns the product.

“This provides the potential to bring a much-needed therapeutic option to patients even sooner than originally planned,” Romano said.

Read more at the Wisconsin State Journal